Cost-effectiveness of universal pneumococcal vaccination for infants in Italy

被引：20
作者：
Marchetti, M
Colombo, GL
机构：
[1] Policlin San Matteo, IRCCS, Lab Med Epidemiol, I-27100 Pavia, Italy
[2] SAVE, I-20149 Milan, Italy
来源：
VACCINE | 2005年 / 23卷 / 37期
关键词：
pneumococcal conjugated vaccine; cost-effectiveness analysis; Markov model;
D O I：
10.1016/j.vaccine.2005.04.033
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
This study aimed at estimating the health and economic outcomes of universal infant vaccination with seven-valent pneumococcal conjugate vaccine (PCV-7) in Italy. A Markov model simulated lifetime evolution of a birth cohort (538,138 children): universal vaccination would avert 769 invasive infections, 18 deaths and 1323 life years. At base-case analysis, universal three-dose vaccination would cost E 26,449 (95% Cl: euro1975-62,075) and euro38,286 (95% Cl: 22,164-70,801) per life year-saved in the societal and the NHS perspective, respectively. In the hypothesis of a 5-year long protection period, vaccination would cost E 32,694 and euro43,115 per life-year saved. Considering yearly incidence of invasive pneumococcal disease reported for Veneto and Sardinia regions, PCV-7 vaccination would result highly cost-effective determining a cost of 6 10,479 and E 16,890 per life year-save in the NHS and the societal perspective, respectively. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4565 / 4576
页数：12
相关论文
共 71 条
[1]  
Abramson JS, 2000, PEDIATRICS, V106, P362
[2]   A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain [J].
Asensi, F ;
De Jose, M ;
Lorente, M ;
Moraga, F ;
Ciuryla, V ;
Arikian, S ;
Casciano, R ;
Vento, M .
VALUE IN HEALTH, 2004, 7 (01) :36-51
[3]   Antimicrobial Resistance Among Clinical Isolates of Streptococcus pneumoniae in North America [J].
Barry, Arthur L. .
AMERICAN JOURNAL OF MEDICINE, 1999, 107 (01) :28-33
[4]   An economic evaluation of universal pertussis vaccination in Italy [J].
Beutels, P ;
Bonanni, P ;
Tormans, G ;
Canale, F ;
Crovari, PC .
VACCINE, 1999, 17 (19) :2400-2409
[5]  
BIGINI R, 1997, ATTI SEZIONE TOSCANA, P55
[6]   Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente [J].
Black, S ;
Shinefield, H ;
Baxter, R ;
Austrian, R ;
Bracken, L ;
Hansen, J ;
Lewis, E ;
Fireman, B .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (06) :485-489
[7]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[8]   Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].
Black, SB ;
Shinefield, HR ;
Ling, S ;
Hansen, J ;
Fireman, B ;
Spring, D ;
Noyes, J ;
Lewis, E ;
Ray, P ;
Lee, J ;
Hackell, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815
[9]   Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine [J].
Black, SB ;
Shinefield, HR ;
Hansen, J ;
Elvin, L ;
Laufer, D ;
Malinoski, F .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) :1105-1107
[10]   Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands [J].
Bos, JM ;
Rümke, H ;
Welte, R ;
Postma, MJ .
CLINICAL THERAPEUTICS, 2003, 25 (10) :2614-2630
12345678